Explore by biomarker

serotype 5, serotype rh74

Duchenne Muscular Dystrophy (DMD), Hemophilia A Patients, Moderate to severe Hemophilia B patients

Microsatellite instability-High (MSI-H)

Colorectal Cancer (CRC)

gene rearrangements, protein expression

Non-Small Cell Lung Cancer (NSCLC)

Functionally active Antithrombin III

Hemophilia A patients with or without factor VIII inhibitors and Hemophilia B patients with or without IX inhibitors

alterations (including mutations)

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

V600, V600 and BRAF fusions, V600E, V600E and V600K, V600E or V600K

Anaplastic Thyroid Cancer (ATC), Colorectal Cancer (CRC), Low-Grade Glioma, Melanoma, Metastatic Colorectal Cancer (mCRC), Non-Small Cell Lung Cancer (NSCLC)

alterations (including mutations)

Breast Cancer, Metastatic Castrate Resistant Prostate Cancer (mCRPC), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer

alterations (including mutations)

Breast Cancer, Metastatic Castrate Resistant Prostate Cancer (mCRPC), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer

Microsatellite instability-High (MSI-H)

Colorectal Cancer (CRC)

Claudin 18 (CLDN18) protein expression (≥75% viable tumor cells (% TC) staining)

Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Tissue factor pathway inhibitor antagonist

Hemophilia A patients with or without factor VIII inhibitors and Hemophilia B patients with or without IX inhibitors

MLH1, PMS2, MSH2 and MSH6

Colorectal Cancer (CRC), Endometrial Carcinoma (EC), Solid Tumors

Microsatellite instability-High (MSI-H)

Colorectal Cancer (CRC)

Exon 19 deletion or exon 21 L858R substitution mutation, Exon 19 deletions or exon 21 L858R, and T790M, Exon 20 insertions, L861Q, G719X and S7681, T790M, protein expression

Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC)

Activating Mutations (SNVs And Exon 20 Insertions), Activating mutations in the tyrosine kinase domain (SNVs in exons 18-21 and exon 20 insertions), HER-2 protein overexpression, HER2 ultralow expression (IHC 0 with membrane staining), HER2-low expression (IHC 1+ or IHC 2+/ISH non-amplified), gene amplification

Biliary Tract Cancer, Breast Cancer, Gastric and Gastroesophageal Cancer, Non-Small Cell Lung Cancer (NSCLC)

ESR1 missense mutations between codons 310 and 547

Breast Cancer

Y646N, Y646F or Y646X (Y646H, Y646S, or Y646C), A682G, and A692V of the EZH2 gene

Follicular Lymphoma Tumor

fusions and select rearrangements

Cholangiocarcinoma

Exon 7: R248C (c.742C>T), S249C (c.746C>G); exon 10: G370C (c.1108G>T) and Y373C (c.1118A>G); and fusions (FGFR3-TACC3v1 and FGFR3-TACC3v3)

Urothelial Cancer

ITD mutations and TKD mutations D835 and I836

Acute Myeloid Leukemia (AML)

protein expression

Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Eligible alleles: HLA-A*02:01, HLA-A*02:02, HLA-A*02:03 or HLA-A*02:06 and their P-group alleles. Exclusion alleles: HLA-A*02:05 and its P-group alleles., HLA-A*02:01

Synovial sarcoma, Uveal Melanoma

BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D and RAD54L alterations

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes and/or positive Genomic Instability Score

Ovarian Cancer

IDH1 R132C, IDH1 R132G, IDH1 R132H, IDH1 R132L, IDH1 R132S, IDH2 R172M, IDH2 R172K, IDH2 R172W, IDH2 R172S, and IDH2 R172G mutations, R132 mutations (R132C, R132H, R132G, R132S, and R132L), Single nucleotide variants

Acute Myeloid Leukemia (AML), Astrocytoma and Oligodendroglioma, Cholangiocarcinoma, Myelodysplastic Syndromes (MDS)

IDH1 R132C, IDH1 R132G, IDH1 R132H, IDH1 R132L, IDH1 R132S, IDH2 R172M, IDH2 R172K, IDH2 R172W, IDH2 R172S, and IDH2 R172G mutations, R140Q, R140L, R140G, R140W, R172K, R172M, R172G, R172S, and R172W

Acute Myeloid Leukemia (AML), Astrocytoma and Oligodendroglioma

D816V

Aggressive Systemic Mastocytosis

G12A, G12D, G12R, G12C, G12S, G12V, G13D, G12C, KRAS wild-type (absence of mutations in codons 12 and 13), Mutations in codons 12 and 13 of KRAS gene, wild-type (absence of mutations in exons 2, 3 and 4)

Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC)

Variants (Pathogenic/Likely Pathogenic) and Variants of Uncertain Significance

Obesity

based on the proton transverse relaxation rate of MRI images

Non-Transfusion-Dependent Thalassemia

MAGE-A4 protein overexpression

Synovial sarcoma

MET protein expression (>= 50% of tumor cells exhibiting strong membrane and/or cytoplasmic staining 3+), single nucleotide variants and indels that lead to MET exon 14 skipping

Non-Small Cell Lung Cancer (NSCLC)

Microsatellite instability-High (MSI-H)

Colorectal Cancer (CRC)

Microsatellite instability-High

Solid Tumors

Not Microsatellite Instability-High (Not MSI-H)

Endometrial Carcinoma (EC)

wild-type (absence of mutations in exons 2, 3 and 4)

Colorectal Cancer (CRC)

fusions

Solid Tumors

fusions

Solid Tumors

fusions

Solid Tumors

Variants (Pathogenic/Likely Pathogenic) and Variants of Uncertain Significance

Obesity

protein expression, protein expression (PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 5% of the tumor area), protein expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), protein expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%]), protein expression (tumor cell staining ≥1%), protein expression [Tumor Proportion Score (TPS) ≥ 50%]

Cervical Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Triple-Negative Breast Cancer (TNBC), Urothelial Cancer

D842V mutation

Gastrointestinal Stromal Tumors (GIST)

PDGFRB gene rearrangement at 5q31~33

Myelodysplastic Syndromes (MDS)

AKT1/PTEN alterations, C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y, alterations (including mutations)

Breast Cancer

Variants (Pathogenic/Likely Pathogenic) and Variants of Uncertain Significance

Obesity

MLH1, PMS2, MSH2 and MSH6

Endometrial Carcinoma (EC)

RET mutations (SNVs, MNVs, and deletions), fusions

Medullary Thyroid Cancer (MTC), Non-Small Cell Lung Cancer (NSCLC), Solid Tumors, Thyroid Cancer (TC)

fusions

Non-Small Cell Lung Cancer (NSCLC)

Microsatellite instability-High (MSI-H)

Colorectal Cancer (CRC)

Microsatellite instability-High (MSI-H)

Colorectal Cancer (CRC)

Microsatellite instability-High (MSI-H)

Colorectal Cancer (CRC)

BCR-ABL fusion

Chronic Myeloid Leukemia (CML)

TMB ≥ 10 mutations per megabase

Solid Tumors

Deletion chromosome 17p (17p-)

B-cell Chronic Lymphocytic Leukemia (CLL)